Artificial Womb Technology Shows Promise for Extreme Preemies

How Does the Artificial Womb Technology Work?

The EXTEND system represents a fundamentally different approach to neonatal care. Unlike traditional incubator-based care, which forces premature infants to breathe air through underdeveloped lungs, the biobag maintains the infant in a fluid-filled environment similar to the womb. The sealed polyethylene bag contains a continuously circulating electrolyte solution that mimics amniotic fluid, allowing fetal breathing movements that are critical for lung maturation. Temperature is precisely regulated to match intrauterine conditions.

Gas exchange — the delivery of oxygen and removal of carbon dioxide — occurs not through the lungs but through a pumpless oxygenator connected to the umbilical cord vessels. The infant's own cardiac output drives blood flow through the circuit, eliminating the need for an external pump and the associated risks of hemolysis and thrombosis. This approach allows the lungs, brain, and other organs to continue developing in a near-physiological state, potentially avoiding the ventilator-induced lung injury and intraventricular hemorrhage that are major causes of morbidity in extreme preemies.

In a landmark preclinical study published in Nature Communications in 2017, Partridge and colleagues at the Children's Hospital of Philadelphia supported lamb fetuses equivalent to approximately 23-24 week human gestation in the biobag for up to 28 days. The lambs demonstrated normal lung maturation with surfactant production, normal brain development without white matter injury, and normal somatic growth. After transitioning from the biobag to air breathing, the lambs showed normal respiratory function — a dramatic improvement over conventional management outcomes at equivalent gestational ages.

What Are the Potential Benefits and Ethical Considerations?

The potential clinical impact is enormous. Extremely premature infants born between 22-28 weeks face high rates of death and disability. At 22 weeks, survival with current NICU care is approximately 10-30% depending on the center, with the majority of survivors experiencing significant neurodevelopmental impairment. Even at 26-28 weeks, where survival generally exceeds 80%, a substantial proportion of survivors develop bronchopulmonary dysplasia (chronic lung disease), and a significant minority experience moderate to severe cerebral palsy or cognitive impairment. By providing a more physiological developmental environment during the critical window of organ maturation, the EXTEND system could potentially reduce these complications substantially.

The ethical implications are significant and actively debated. The technology could effectively lower the threshold of viability, raising questions about when life-sustaining treatment should be offered or withheld. An FDA advisory committee convened in 2023 to review the regulatory and ethical framework for this novel technology, carefully examining how to classify and evaluate the device. Initial trial designs have proposed enrolling only infants who would otherwise face very poor prognoses due to extreme prematurity. Informed consent processes, clear enrollment criteria, and ethics oversight committees are integral to the trial design.

Other concerns include equitable access (the technology will initially be available only at specialized centers), the psychological impact on parents, and the regulatory classification of the device — the FDA has had to consider new regulatory approaches specifically for this technology, as it does not fit neatly into existing frameworks for either medical devices or organ support systems. The estimated cost per treatment course is not yet established but will likely be substantial given the complexity of the system.